MedTrace Logo

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2025-03-26

No results posted yet for this study

Summary

The study objective is to identify the earliest changes in energy substrate metabolism in patients with cardiomyopathies (CMP). To achieve this objective, we plan first to test the hypothesis that patients with CMP present focal alterations in myocardial hyperpolarized \[1-13C\]pyruvate flux.

Conditions

Interventions

DIAGNOSTIC_TEST

Hyperpolarized 13C-Pyruvate

All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Vlad G Zaha, MD, PhD · Advanced Imaging Research Center

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2023-05-17
Completion
2023-05-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03057002 on ClinicalTrials.gov